<?xml version="1.0" encoding="UTF-8"?>
<p>This approach is most likely to be successful with NoV VLPs as NoV naturally infects the gastrointestinal system and, therefore, is resistant to denaturation and digestion in the oral-gastrointestinal tract [
 <xref ref-type="bibr" rid="CR000831">31</xref>, 
 <xref ref-type="bibr" rid="CR0008107">107</xref>]. Moreover, their resemblance to the native virus allows them to be efficiently sampled by the “M” cells of the gut epithelium and transported into GALT for antigen processing and presentation [
 <xref ref-type="bibr" rid="CR0008102">102</xref>]. Thus, VLPs produced in edible plants represent a novel and cost-effective approach to establishing gut mucosal immunity by oral delivery [
 <xref ref-type="bibr" rid="CR0008135">135</xref>–
 <xref ref-type="bibr" rid="CR0008137">137</xref>]. As a vaccine is required to have a defined dosage unit, this strategy may face regulatory hurdles for commercialization in developed countries [
 <xref ref-type="bibr" rid="CR0008102">102</xref>, 
 <xref ref-type="bibr" rid="CR0008123">123</xref>, 
 <xref ref-type="bibr" rid="CR0008124">124</xref>]. However, this strategy may eventually offer a feasible option for commercial vaccine delivery by oral route, especially as more consistent VLP accumulation per unit of plant tissue is being achieved by the new generation of expression vectors.
</p>
